Monday, 17 May 2021

BioLargo Q1 2021 Quarterly Report Highlights Improving Balance Sheet and Status of PFAS Commercial Pilots in Emerging Multi-Billion Dollar Market

 Investor Webcast Scheduled for Wednesday, May 19, 2021 at 4:30pm ET 

Westminster, CA – May 17, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q with the SEC today for the three months ended March 31, 2021 (www.biolargo.com/sec-filings). The company has summarized some of the most important points from the report for its investors and provided insights into its strategy for expanding sales of its environmental technologies in existing and new market segments through 2021.

The company also announced an investor webcast to be held on Wednesday, May 19, 2021, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/41343

BioLargo investors are also encouraged to attend the company’s online-only Annual Meeting of Stockholders on June 15, 2021, the details of which can be found at www.biolargoreport.com.

Dennis P. Calvert, President and CEO of BioLargo said, “We are now in a strong cash position, have reliable financing resources, and have retired all but $456,000 of our convertible debt. With our financial condition continuing to improve, our team of highly qualified engineers, scientists, and business professionals are uniquely positioned to commercialize our expanding portfolio of innovative environmental technologies, like our AEC system that removes PFAS chemicals from drinking water.”

According to Environmental Business International, the market for PFAS treatment, which BioLargo’s new AEC technology aims to address, will grow to be an $80+ billion market in the US over the next few years, and that there are more than 200 contaminated military sites which urgently require PFAS remediation. Mr. Calvert commented, “Our hard work to develop and commercialize an economical and eco-conscious solution to this huge problem puts us ahead of the curve to address this burgeoning market. Our PFAS remediation technology represents a massive and timely commercial opportunity, with its first commercial pilots starting soon.”

Financial highlights from the 10-Q:

  • Consolidated revenue for the three months ended March 31, 2021 was $571,000, a 30% increase compared to the prior year’s period. 
  • Due in large part to an almost 90% decrease in interest expense as a result of payment and conversion of debt instruments, the company’s net loss for the three months ended March 31, 2021, decreased by 28% as compared to the prior year’s period.
  • In 2021, the company has retired $650,000 in debt. Since December 31, 2019, the company has reduced its debt by over $3.6 million. Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA/PPP loans and fixed-price convertible debt now remain on BioLargo’s balance sheet. Of the fixed price convertible debt, we are currently negotiating the payoff and partial conversion of the $406,000 due in August 2021, and $50,000 is due in two years.
  • As a result of the company’s improved balance sheet, its total stockholder equity is now approximately $772,000. Management expects this trend will be critical to the company as it continues to evaluate the opportunity to uplist its stock to a national stock exchange.

Commercial, operational, and R&D highlights:

  • Established a partnership with Garratt-Callahan, a national industrial water treatment company, to develop and sell custom wastewater treatment and recycling equipment. This dynamic partnership is expanding to include the sales of other BioLargo products and services to Garratt-Callahan customers.
  • The first commercial-scale unit of the company’s Advanced Oxidation System (AOS) water treatment technology began a pilot project at a municipal wastewater treatment plant near Montréal, Québec.
  • BioLargo’s treatment technology for per- and polyfluoroalkyl substances (PFAS) underwent a technical advancement, which was the subject of a recently submitted patent application, that improves the lifespan of the AEC’s membranes and the technology’s overall commercial outlook.
  • The company is working with prospective partners to plan and schedule the first commercial pilots for the AEC technology as soon as possible.
  • BioLargo Engineering’s project backlog grew to a value of over $2 million, to be executed over the next 12-18 months.
  • ONM Environmental added a new air quality control product technology called EcoMist®, a technology that sprays trash bins with odor control product during trash collection.
The commercial-scale AOS being unpacked at the pilot in Montreal


 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 12 May 2021

BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time

Westminster, CA – May 12, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public. The webcast and conference call will be held to review the company’s financial results, discuss recent company developments, and conduct a question-and-answer session.

The webcast, accompanying presentation materials, and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/41343

Teleconference Domestic:

844-369-8770

Teleconference International:

862-298-0840

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Thursday, May 19, 2022

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/41343

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

41343

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 10 May 2021

BioLargo to Present at The Benzinga Global Small Cap Conference on Friday May 14th

Westminster, CA – May 10, 2021– BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company, announced that it will be presenting at the Benzinga Global Small Cap Conference on Friday May 14, 2021, at 10:10 a.m. Eastern Time. This conference offers a great opportunity for existing and prospective shareholders to learn about BioLargo’s growth prospects in the cleantech and environmental solutions industry. Leaders from around the world are increasingly focused on cleantech as the green energy revolution unfolds globally and the demand for these technologies continues rising.

“Ours is an incredibly dynamic business, and the advancements in our commercial activities in areas like PFAS remediation and water treatment are really shaping our potential for growth as a total cleantech solutions provider,” said BioLargo CEO Dennis P. Calvert. “I am looking forward to talking about these and other new developments in our company. Conferences like the Benzinga Small Cap are integral to our efforts to reach new retail investors and spread the word about BioLargo to new audiences like the cleantech investing community.”  

The Benzinga Global Small Cap conference is free to attend. Register here:  https://www.benzinga.com/events/small-cap/global/

 

About the Benzinga Cleantech Small Cap Conference

The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the global Small Cap audience in an intimate, virtual setting.  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include without limitation those about BioLargo’s (the “Company”) expectations, anticipated revenue, and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. More information on the risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 28 April 2021

BioLargo/BKT Joint Venture (Odin) Update

Last year, BioLargo formed a joint venture with South Korean wastewater industry leader BKT Co. and its American subsidiary Tomorrow Water to launch BioLargo’s disruptive air quality control products into the Asian market. The joint venture, named Odin, sought to introduce BioLargo’s CupriDyne® Clean odor and VOC eliminator first in South Korea and Vietnam, where industry operators in wastewater treatment, waste handling, and agriculture can benefit greatly from this eco-friendly product’s ability to rapidly eliminate odor-causing compounds and VOCs.

We’re pleased to say the joint venture is making progress. Late last year, Odin moved its headquarters to the Korea Water Cluster in Daegu, a center for high-tech environmental innovation in South Korea.

Recently, the company began manufacturing the product in its new facilities. Odin began highlighting the product and its initial pilot deployments at BKT’s website. You can check that out here (ensure you turn translation on in your browser): https://www.bkt21.co.kr/magazine/2021/4/19/odin

Some images from the post are provided here!

You can also check out Odin’s recently launched product website at: http://odinodor.com/


Pre-treatment facility in Ganghwa livestock manure public treatment facility with Odin applied to  impurities treatment unit (left) and dehydration unit (right)



Uijeongbu Luoyang Water Sarang Park with Odin spraying system applied to the hopper room dehydration cake in the lower part of the arm roll box.


Monday, 26 April 2021

USA Today Piece: BioLargo technology tackles water crisis caused by ‘forever chemicals’

This piece originally appeared in USA Today's 2021 Sustainability Edition. You can view the full online version on page 71 at: https://usatodayspecial-va.newsmemory.com/?special=Green+Living&date=20210421


A U.S. technology company is rolling out pilot projects for their promising solution to the environmental crisis created by PFAS, so-called forever chemicals found in drinking water supplies and groundwater throughout the U.S. 

BioLargo, Inc. (OTCQB:BLGO) an environmental technologies innovator headquartered in Westminster, Ca., has developed groundbreaking technology that removes PFAS chemicals from water quickly and economically, without creating the mountains of carbon waste associated with current technologies.

PFAS, or per- and polyfluoroalkyl substances, are fueling a crisis in the U.S. and other industrialized nations because of their longevity in the environment and their link to various cancers, thyroid issues, fetal developmental problems, high cholesterol and other medical disorders. These synthetic chemicals are used in the manufacture of countless consumer items, including food packaging, cleaning supplies and non-stick cookware, as well as firefighting foam. As a by-product of manufacturing, PFAS can move from contaminated soil at industrial sites, landfills and airports into groundwater and eventually aquifers, nearby wells or municipal water sources.

PFAS have been found in the drinking water of more than 1,400 U.S. communities. The new Biden administration has declared PFAS clean-up a top priority in its ambitious environmental agenda and recently confirmed EPA head Michael Reagan has promised strong action on the issue.

BioLargo’s water-treatment technology, called the AEC (Aqueous Electrostatic Concentrator), uses electrolysis to extract PFAS molecules from water and deposit them on membranes. A third-party analysis by the University of Tennessee found that the AEC captures 99.995 percent of the PFAS from contaminated water. BioLargo is now building commercial-sized units to be used in pilot projects in water supplies in California, Wisconsin and the western U.S. There is also a significant market for AEC technology in groundwater remediation near industrial sites, military bases and airports.

Randall Moore, President of BioLargo’s engineering subsidiary, says the standard technology for removing PFAS from contaminated water involves activated carbon filtration. While carbon works relatively well, the process generates tons of PFAS-laden waste. Municipal water services would have to ship hundreds of containers of carbon waste to be incinerated, which could create toxic volatile air contaminants and greenhouse gases.

With BioLargo’s AEC technology, “at the end of a treatment cycle, instead of having 80,000 pounds of waste, we might have 85 pounds,” says Moore. BioLargo is also working on a sustainable way of extracting PFAS from the spent membrane, destroying the PFAS and sending the membrane residue to a landfill.

Thursday, 22 April 2021

BioLargo’s Sustainable PFAS Solution Hits Major Technical Milestone, Paving Way for Commercial Trials

Westminster, CA – April 22, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, has achieved a critical technical milestone in the development and commercialization of its sustainable treatment technology for PFAS-contaminated water (per- and polyfluoroalkyl substances), called the Aqueous Electrostatic Concentrator (AEC). This development, which involved a re-design of the AEC’s electrical configuration, dramatically improves its operating and maintenance costs. With this technological hurdle out of the way, the company can now finalize agreements for the technology’s first demonstration pilots and commercial trials.

PFAS are a group of man-made chemicals used in the manufacture of countless household, commercial, and industrial goods. Because of their resilient chemical structure, they accumulate in rivers, lakes, and groundwater, as well as in humans and other living things. They have been linked to chronic health problems such as cancer, hormone disorders, and increased cholesterol. The Biden administration has made regulation of PFAS in drinking water a top priority, having recently issued final regulatory determinations for the two most common PFAS compounds under the Safe Drinking Water Act (SDWA).

The most common water treatment process for removing PFAS is filtration by granulated activated carbon (GAC). This technique has a significant downside, however: it generates huge volumes of PFAS-laden carbon waste that requires disposal, usually at a landfill or by incineration, both of which are costly and have poor environmental outcomes. In comparison, the BioLargo AEC uses electrophoresis to collect PFAS onto proprietary membranes, using little electricity and requiring a diminutive physical footprint. The AEC is projected to have significantly more affordable operating costs and generate a fraction of the PFAS-laden waste compared to carbon filtration.

BioLargo Engineering, Science & Technologies has succeeded in modifying the AEC to extend the useful lifespan of its specialized membranes, which are a crucial component of the technology. This advancement has improved the operating and maintenance metrics for the technology, potentially reducing the frequency of membrane replacement by a factor of six. While the AEC was already being prepared for its first commercial pilots, this enhancement improves the technology’s long-term costing metrics for customers and is expected to improve the technology’s rate of adoption by PFAS treatment customers. BioLargo has already patented the AEC and has filed at least one patent application to expand the existing intellectual property coverage for the AEC with the new modification.

Dennis P. Calvert, BioLargo’s CEO commented on the technology’s future, “With this advancement to the AEC’s design, our next step is commercial trials. We can now finalize the details of several trials at municipalities on the West Coast and in the American Midwest as well as a major federal government organization. BioLargo Engineering is already working to build the demonstration units for those projects. We believe the success of these initial pilot projects will provide the commercial validation data that will convince State authorities to adopt the technology en masse.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act – caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 14 April 2021

BioLargo Inc. to Present at Benzinga Cleantech Small Cap Conference on April 22nd at 11:20am EST

Westminster, CA – April 14, 2021– BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company will be presenting at the Benzinga Cleantech Small Cap Conference on Earth Day, April 22, 2021, at 11:20am EST. The company invites its shareholders and all interested parties to learn more about BioLargo, cleantech, and environmental remediation investment opportunities.

“If you haven’t heard about BioLargo in a while, then you only know half the story,” said BioLargo CEO Dennis P. Calvert. “We’ve grown into a serious contender in the cleantech solutions industry, and we have new water remediation technologies that can help solve a lot of pressing challenges in the world. We are excited to share our progress with the markets as we continue to provide knockout solutions to challenging global problems.”

Benzinga hosts investor conferences focused on clean technologies, also known as “cleantech”, which are technologies that foster positive environmental outcomes such as reduced energy usage, water resource stewardship, and minimization of waste. Industry leaders around the world are increasingly focused on cleantech as the demand for these technologies rises globally each year.

Sign up for free: https://www.benzinga.com/events/small-cap/clean-tech/

 

About the Benzinga Cleantech Small Cap Conference

The Benzinga Cleantech Small Cap Conference bridges the gap between cleantech companies, investors, and traders. Discover the companies in the cleantech industry who are moving the world forward through accessible green energy, energy efficiency, and innovative sustainability solutions.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.